Abstract

19073 Background: Topotecan is FDA approved for the treatment of sensitive relapse SCLC using a 5-day IV schedule. A 4 mg/m2 weekly IV schedule studied by our group was associated with low grade (G...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.